In Europe, the time between regulatory approval and population access for vaccines exceeds that for other pharmaceutical products. This difference has been shown to be linked to the recommendation phase, where NITAGs assess new vaccines before implementation into vaccination programmes and coverage by health insurance. The objective of this research was to study and compare NITAGs’ policies and decision-making processes in 9 European and 4 non-European countries.